Abstract
Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Current Drug Targets
Title:Molecular Pathophysiology of Priapism: Emerging Targets
Volume: 16 Issue: 5
Author(s): Uzoma A. Anele, Belinda F. Morrison and Arthur L. Burnett
Affiliation:
Keywords: Adenosine, nitric oxide, opiorphins, rho kinase, recurrent ischemic priapism treatment, testosterone.
Abstract: Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.
Export Options
About this article
Cite this article as:
Anele A. Uzoma, Morrison F. Belinda and Burnett L. Arthur, Molecular Pathophysiology of Priapism: Emerging Targets, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141111111842
DOI https://dx.doi.org/10.2174/1389450115666141111111842 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Platelet in Progression of Atherosclerosis: A Potential Target in Diabetic Patients
Current Diabetes Reviews Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design The Protein Therapy of Kallikrein in Cerebral Ischemic Reperfusion Injury
Current Medicinal Chemistry From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Crystal Structure of a Cu,Zn Superoxide Dismutase From the Thermophilic Fungus <i>Chaetomium thermophilum</i>
Protein & Peptide Letters Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures
Current Drug Metabolism Review of the Biological Activity of Maslinic Acid
Current Drug Targets Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia
Current Neurovascular Research Current Issues with Glycoprotein IIb-IIIa Antagonists
Current Drug Targets Curcumin Targets p53-Fibrinolytic System in TGF-β1 Mediated Alveolar Epithelial Mesenchymal Transition in Alveolar Epithelial Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets subject Index To Volume 2
Current Medicinal Chemistry - Central Nervous System Agents Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists
Current Drug Targets Plasticity in Uterine Innervation: State of the Art
Current Protein & Peptide Science